טוען...

Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Aged ≥ 60 Years with B-Cell Lymphoma

Myeloablative therapy and autologous stem cell transplant (ASCT) is underutilized in older patients with B-cell non-Hodgkin (B-NHL) lymphoma. We hypothesized that myeloablative doses of (131)I-tositumomab could be augmented by concurrent fludarabine based on preclinical data indicating synergy. Pati...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
Main Authors:	Gopal, Ajay K., Gooley, Ted A., Rajendran, Joseph G., Pagel, John M., Fisher, Darrell R., Maloney, David G., Appelbaum, Frederick R., Cassaday, Ryan D., Shields, Andrew, Press, Oliver W.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	2014
נושאים:	Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4019701/ https://ncbi.nlm.nih.gov/pubmed/24530971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2014.02.004
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Aged ≥ 60 Years with B-Cell Lymphoma

פריטים דומים